Tezuka S, Ueno M, Kobayashi S, Hamaguchi T, et al. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. Pancreatology 2022 Jun 9. pii: S1424-3903(22)00194.
PMID: 35705458